Clinical trial
Endostatin in Treating Patients With Advanced Refractory Solid Tumors
NCT00004872 · University of Wisconsin, Madison, Other · Completed
Key facts
| NCT number | NCT00004872 |
|---|---|
| Title | Endostatin in Treating Patients With Advanced Refractory Solid Tumors |
| Official title | Phase I Study of Endostatin in Advanced Cancer Patients |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | recombinant human endostatin |
| Start date | Mar 1, 2000 |
| First posted | Apr 28, 2004 |
| Last update posted | Dec 13, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: